Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...
Insightful Moves in the European Market: A Detailed Analysis of Recent Investments
Invesco EQV European Equity Fund (Trades, Portfolio), a notable mutual fund under Invesco Ltd., has recently disclosed its N-PORT filing for the third quarter of 2024. Established on November 3, 1997, the fund targets high-growth opportunities across both developed and emerging European markets. It focuses on a diversified portfolio of reasonably priced, quality companies, emphasizing strong fundamentals and sustainable earnings growth.
Summary of New Buys
The fund has strategically expanded its portfolio by adding four new stocks. Noteworthy among them is Teva Pharmaceutical Industries Ltd (NYSE:TEVA), with a purchase of 341,255 shares, making up 1.25% of the portfolio and valued at $5.95 million. Following closely is Edenred SE (XPAR:EDEN), with 106,662 shares that represent about 0.93% of the portfolio, amounting to 4.44 million. Another significant addition was Arkema SA (XPAR:AKE), comprising 41,226 shares or 0.78% of the portfolio, valued at 3.72 million.
Key Position Increases
The fund has also increased its stakes in seven stocks, with BAE Systems PLC (LSE:BA.) leading the pack. An additional 125,385 shares were acquired, bringing the total to 469,231 shares. This adjustment marks a substantial 36.47% increase in share count, impacting the portfolio by 0.44% and valued at 7.83 million. The second largest increase was in London Stock Exchange Group PLC (LSE:LSEG), with an additional 12,753 shares, totaling 58,652 shares and valued at 7.14 million.
Key Position Reductions
Conversely, the fund reduced its position in 23 stocks. The most significant reductions include FinecoBank SpA (MIL:FBK), which saw a decrease of 196,447 shares, resulting in a 26.15% reduction and a 0.66% portfolio impact. The stock traded at an average price of 14.91 during the quarter. Schneider Electric SE (XPAR:SU) also saw a reduction of 9,630 shares, marking an 18.87% decrease and a 0.48% impact on the portfolio, with the stock trading at an average price of 227.47 during the quarter.
Portfolio Overview
As of the third quarter of 2024, Invesco EQV European Equity Fund (Trades, Portfolio)'s portfolio included 56 stocks. The top holdings were 4.41% in Novo Nordisk AS (OCSE:NOVO B), 3.79% in Investor AB (OSTO:INVE B), 3.33% in RELX PLC (LSE:REL), 3.04% in ASML Holding NV (XAMS:ASML), and 2.94% in IG Group Holdings PLC (LSE:IGG). The holdings are predominantly concentrated across 10 of the 11 industries, including Industrials, Healthcare, Financial Services, Consumer Cyclical, Energy, Consumer Defensive, Communication Services, Technology, Basic Materials, and Real Estate.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.